Breast cancer

Updated 09 November 2017

Control therapy side effects

Hormonal breast cancer treatment increases menopausal symptoms in women.

Among postmenopausal women receiving adjuvant therapy for early breast cancer, exemestane is associated with fewer hot flashes than is tamoxifen, but it also causes more sleep problems, according to a study published the Journal of Clinical Oncology.

"Hormonal breast cancer treatment increases menopausal symptoms in women," note Dr Stephen E. Jones and colleagues from US Oncology Research Inc., Houston.

Identifying common symptoms
The investigators used questionnaires, completed by more than 1 500 women to assess 10 common symptoms in the first year of a clinical trial of tamoxifen or exemestane. Tamoxifen is sold under the trade name Nolvadex, and exemestane is sold under the trade name Aromasin.

The patients had completed surgery and chemotherapy for early breast cancer. All of the women had hormone receptor-positive cancers, which respond to these two agents.

The prevalence of the initial symptoms ranged from 2 percent (for vaginal bleeding) to 75 percent (for fatigue).

Patients who received tamoxifen experienced significantly more vaginal discharge than those who received exemestane. Those who received exemestane had more bone and muscle aches, vaginal dryness, difficulty sleeping and decreased libido.

Necessary evil
In both treatment groups, hot flash scores peaked at about 3 months and decreased thereafter. As mentioned, patients in the tamoxifen group had a significantly higher mean hot flash score at 12 months than those in the exemestane group.

"These are common complaints and the treatments used make some worse," Jones commented to Reuters Health. "Oncologists and other oncology health professionals need to be aware of the commonplace nature (of these side effects) and attempt to help wherever possible," he said. For example, he suggested it may be necessary to treat the hot flashes if they are affecting the patient's quality of life. - (Reuters Health) SOURCE: Journal of Clinical Oncology, October 20, 2007.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules